JP2005519635A - 活性クロマチンエレメントを含むｄｎａマイクロアレイおよびそれを用いた包括的プロファイリング - Google Patents
活性クロマチンエレメントを含むｄｎａマイクロアレイおよびそれを用いた包括的プロファイリング Download PDFInfo
- Publication number
- JP2005519635A JP2005519635A JP2004503602A JP2004503602A JP2005519635A JP 2005519635 A JP2005519635 A JP 2005519635A JP 2004503602 A JP2004503602 A JP 2004503602A JP 2004503602 A JP2004503602 A JP 2004503602A JP 2005519635 A JP2005519635 A JP 2005519635A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- array
- profile
- cell
- active chromatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010077544 Chromatin Proteins 0.000 title claims abstract description 65
- 210000003483 chromatin Anatomy 0.000 title claims abstract description 65
- 238000000018 DNA microarray Methods 0.000 title claims description 26
- 238000000034 method Methods 0.000 claims abstract description 168
- 210000004027 cell Anatomy 0.000 claims abstract description 98
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 210000001519 tissue Anatomy 0.000 claims abstract description 34
- 230000001105 regulatory effect Effects 0.000 claims abstract description 32
- 108020004414 DNA Proteins 0.000 claims description 126
- 239000000523 sample Substances 0.000 claims description 73
- 239000012634 fragment Substances 0.000 claims description 68
- 150000007523 nucleic acids Chemical group 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 238000009739 binding Methods 0.000 claims description 29
- 238000002493 microarray Methods 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 21
- 206010020751 Hypersensitivity Diseases 0.000 claims description 20
- 101710163270 Nuclease Proteins 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 238000002372 labelling Methods 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 18
- 238000012986 modification Methods 0.000 claims description 18
- 210000004940 nucleus Anatomy 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 14
- 238000009396 hybridization Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 10
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 10
- 108010042407 Endonucleases Proteins 0.000 claims description 9
- 102000004533 Endonucleases Human genes 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 238000001994 activation Methods 0.000 claims description 7
- 238000010367 cloning Methods 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000000126 in silico method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000003252 repetitive effect Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 4
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 101710183280 Topoisomerase Proteins 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 238000003752 polymerase chain reaction Methods 0.000 claims description 4
- 238000000527 sonication Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000003964 Histone deacetylase Human genes 0.000 claims description 3
- 108090000353 Histone deacetylase Proteins 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 230000007613 environmental effect Effects 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 239000006249 magnetic particle Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 238000003499 nucleic acid array Methods 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims 10
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 6
- 239000002751 oligonucleotide probe Substances 0.000 claims 6
- 238000004113 cell culture Methods 0.000 claims 4
- 230000032683 aging Effects 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 241000252212 Danio rerio Species 0.000 claims 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 102000055027 Protein Methyltransferases Human genes 0.000 claims 1
- 108700040121 Protein Methyltransferases Proteins 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000005257 nucleotidylation Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 108091035233 repetitive DNA sequence Proteins 0.000 claims 1
- 102000053632 repetitive DNA sequence Human genes 0.000 claims 1
- 238000003491 array Methods 0.000 abstract description 30
- 238000000899 pressurised-fluid extraction Methods 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 230000003321 amplification Effects 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000003446 ligand Substances 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000008836 DNA modification Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- -1 Styl Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000005783 single-strand break Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 208000037088 Chromosome Breakage Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000030933 DNA methylation on cytosine Effects 0.000 description 2
- 231100001074 DNA strand break Toxicity 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 231100000005 chromosome aberration Toxicity 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000007247 enzymatic mechanism Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 238000011066 ex-situ storage Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LZJPDRANSVSGOR-UHFFFAOYSA-N 1-(4-azidophenyl)-2-bromoethanone Chemical compound BrCC(=O)C1=CC=C(N=[N+]=[N-])C=C1 LZJPDRANSVSGOR-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101001017206 Coxiella burnetii (strain RSA 493 / Nine Mile phase I) Histone-like protein Hq1 Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101000953091 Enterobacteria phage P4 Uncharacterized protein ORF88 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- FUSGACRLAFQQRL-UHFFFAOYSA-N N-Ethyl-N-nitrosourea Chemical compound CCN(N=O)C(N)=O FUSGACRLAFQQRL-UHFFFAOYSA-N 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010263 activity profiling Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002508 contact lithography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000464 effect on transcription Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29003601P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/015032 WO2003095608A2 (en) | 2001-05-11 | 2002-05-13 | Dna microarrays comprising active chromatin elements and comprehensive profiling therewith |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519635A true JP2005519635A (ja) | 2005-07-07 |
| JP2005519635A5 JP2005519635A5 (enExample) | 2006-01-05 |
Family
ID=29420206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503602A Pending JP2005519635A (ja) | 2001-05-11 | 2002-05-13 | 活性クロマチンエレメントを含むｄｎａマイクロアレイおよびそれを用いた包括的プロファイリング |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030170689A1 (enExample) |
| EP (1) | EP1407053A4 (enExample) |
| JP (1) | JP2005519635A (enExample) |
| AU (1) | AU2002367838A1 (enExample) |
| CA (1) | CA2460679A1 (enExample) |
| WO (1) | WO2003095608A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610489B2 (en) * | 2000-04-28 | 2003-08-26 | Sangamo Biosciences, Inc. | Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions |
| US20040014086A1 (en) * | 2001-05-11 | 2004-01-22 | Regulome Corporation | Regulome arrays |
| CA2450814A1 (en) * | 2001-07-02 | 2003-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | Microarrays for cell phenotyping and manipulation |
| US20110151438A9 (en) | 2001-11-19 | 2011-06-23 | Affymetrix, Inc. | Methods of Analysis of Methylation |
| US20050003369A1 (en) * | 2002-10-10 | 2005-01-06 | Affymetrix, Inc. | Method for depleting specific nucleic acids from a mixture |
| WO2005118873A2 (en) * | 2004-05-28 | 2005-12-15 | Cemines, Inc. | Compositions and methods for detecting open chromatin and for genome-wide chromatin state profiling |
| GB0419419D0 (en) * | 2004-09-01 | 2004-10-06 | Medical Res Council | Method |
| CA2607327A1 (en) * | 2005-04-29 | 2006-11-09 | The Regents Of The University Of California | Antibodies against histone modifications for clinical diagnosis and prognosis of cancer |
| US20060292585A1 (en) * | 2005-06-24 | 2006-12-28 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| US7901882B2 (en) | 2006-03-31 | 2011-03-08 | Affymetrix, Inc. | Analysis of methylation using nucleic acid arrays |
| WO2008024473A2 (en) * | 2006-08-24 | 2008-02-28 | University Of Massachusetts Medical School | Mapping of genomic interactions |
| US8076070B2 (en) * | 2008-08-06 | 2011-12-13 | University Of Southern California | Genome-wide chromosome conformation capture |
| US10526641B2 (en) * | 2014-08-01 | 2020-01-07 | Dovetail Genomics, Llc | Tagging nucleic acids for sequence assembly |
| WO2016154540A1 (en) | 2015-03-26 | 2016-09-29 | Dovetail Genomics Llc | Physical linkage preservation in dna storage |
| US10975417B2 (en) | 2016-02-23 | 2021-04-13 | Dovetail Genomics, Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
| CN109477101B (zh) | 2016-05-13 | 2022-11-18 | 多弗泰尔基因组学有限责任公司 | 从保存的样品中回收长范围连锁信息 |
| US20190234874A1 (en) * | 2016-07-19 | 2019-08-01 | Altius Institute For Biomedical Sciences | Methods for fluorescence imaging microscopy |
| CN106987629B (zh) * | 2017-03-31 | 2021-01-15 | 上海市第一妇婴保健院 | 一种在单细胞水平上检测基因组上核小体排布的方法 |
| AU2018304396B2 (en) | 2017-07-19 | 2025-01-23 | Altius Institute For Biomedical Sciences | Methods and compositions for viral Nano-FISH |
| EP3803404A4 (en) | 2018-06-06 | 2022-03-23 | Ramot at Tel-Aviv University Ltd. | MULTI-SAMPLE ARRAY CHIP FOR QUANTIFICATION OF DNA CHANGE |
| GB2581152A (en) * | 2019-02-05 | 2020-08-12 | Univ Oxford Innovation Ltd | Production of 3C library |
| CN112973592B (zh) * | 2019-12-16 | 2022-12-09 | 天津大学 | 一种基于阵列式喷墨打印的高通量dna合成装置与方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610053A (en) * | 1993-04-07 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
| US6165709A (en) * | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
| US5972608A (en) * | 1997-08-27 | 1999-10-26 | University Of Massachusetts | Assays and reagents for chromatin remodeling enzymes and their modulators |
-
2002
- 2002-05-13 WO PCT/US2002/015032 patent/WO2003095608A2/en not_active Ceased
- 2002-05-13 CA CA002460679A patent/CA2460679A1/en not_active Abandoned
- 2002-05-13 EP EP02807414A patent/EP1407053A4/en not_active Withdrawn
- 2002-05-13 AU AU2002367838A patent/AU2002367838A1/en not_active Abandoned
- 2002-05-13 JP JP2004503602A patent/JP2005519635A/ja active Pending
- 2002-12-12 US US10/319,440 patent/US20030170689A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030170689A1 (en) | 2003-09-11 |
| AU2002367838A1 (en) | 2003-11-11 |
| CA2460679A1 (en) | 2003-11-20 |
| WO2003095608A2 (en) | 2003-11-20 |
| EP1407053A2 (en) | 2004-04-14 |
| EP1407053A4 (en) | 2004-09-29 |
| WO2003095608A3 (en) | 2004-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519635A (ja) | 活性クロマチンエレメントを含むｄｎａマイクロアレイおよびそれを用いた包括的プロファイリング | |
| Gilbert | Evaluating genome-scale approaches to eukaryotic DNA replication | |
| Schulze et al. | Navigating gene expression using microarrays? a technology review. | |
| Schones et al. | Genome-wide approaches to studying chromatin modifications | |
| Barrett et al. | Microarrays: the use of oligonucleotides and cDNA for the analysis of gene expression | |
| US20020034753A1 (en) | Novel assay for nucleic acid analysis | |
| US7189509B2 (en) | Analysis of gene expression profiles using sequential hybridization | |
| WO2000009756A1 (en) | Adapter directed expression analysis | |
| JP2004524044A (ja) | 制限部位タグ付きマイクロアレイを用いたハイスループットゲノム解析方法 | |
| CA2555377A1 (en) | Genetic analysis by sequence-specific sorting | |
| US6340565B1 (en) | Determining signal transduction pathways | |
| JP2004504059A (ja) | 転写された遺伝子を分析、及び同定するための方法、及びフインガープリント法 | |
| US20040014086A1 (en) | Regulome arrays | |
| Busch et al. | Profiling a plant: expression analysis in Arabidopsis | |
| Landegren et al. | Locked on target: strategies for future gene diagnostics | |
| AU2003276609B2 (en) | Qualitative differential screening for the detection of RNA splice sites | |
| US20070003929A1 (en) | Method for identifying, analyzing and/or cloning nucleic acid isoforms | |
| Yadav et al. | Single-cell epigenomics: Methods and translation | |
| Andersson et al. | Shotgun sequencing and microarray analysis of RDA transcripts | |
| JP2007185183A (ja) | ２５塩基を超えるタグを固定化したアレイ（ＳｕｐｅｒＳＡＧＥ−Ａｒｒａｙ）による遺伝子発現解析 | |
| Ye | Serial analysis of gene expression in human diseases | |
| Ira et al. | Applications of Deep Sequencing to Developmental Systems | |
| US20060073482A1 (en) | Analysis of biological samples | |
| Katyal et al. | DNA MICROARRAY: AN INTERDISCIPLINARY APPROACH AND ITS APPLICATIONS | |
| WO2004007768A1 (en) | Method to analyze polymeric nucleic acid sequence variations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050512 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050512 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080814 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080821 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090203 |